Scientific Reports (Aug 2024)

Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study

  • Marco Luigetti,
  • Francesca Vitali,
  • Angela Romano,
  • Maria Ausilia Sciarrone,
  • Valeria Guglielmino,
  • Michelangelo Ardito,
  • Andrea Sabino,
  • Serenella Servidei,
  • Geny Piro,
  • Carmine Carbone,
  • Francesca Graziani,
  • Rosa Lillo,
  • Pietro Manuel Ferraro,
  • Guido Primiano

DOI
https://doi.org/10.1038/s41598-024-69123-x
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Hereditary transthyretin (ATTRv) amyloidosis is a rare, adult-onset, progressive, multisystemic condition caused by TTR pathogenic variants. Reliable biomarkers are needed to allow early diagnosis and to monitor disease severity and progression. We measured serum concentrations of growth differentiation factor-15 (GDF-15) and uromodulin (Umod) in ATTRv patients to evaluate correlations with standard markers of disease severity (FAP stage and PND score). Blood samples were collected from 16 patients diagnosed with ATTRv amyloidosis and a verified TTR variant and from 26 healthy controls. ATTRv patients were stratified by clinical phenotype (neurologic vs. mixed), genotype (V30M vs. non-V30M), and disease severity. We found significantly higher levels of serum GDF-15 in ATTRv patients compared with controls. Mean serum Umod levels were significantly lower in patients with ATTRv than controls. A positive correlation was found between serum Umod and estimated glomerular filtration rate (eGFR), while an inverse correlation was found with cystatin C levels. Conversely, GDF-15 showed a negative correlation with eGFR, and a direct correlation with cystatin C levels. No correlation was demonstrated between GDF-15 or Umod levels and traditional cardiac biomarkers. The results identify alteration of serum levels of GDF-15 and Umod in ATTRv amyloidosis.

Keywords